Altos Labs
Reversing aging at the cellular level
San Francisco, CA, US
Biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience.
How We Help
Problem Statement
The decline of cell health and resilience, often associated with aging and disease.
Core Technology
Partial epigenetic cell reprogramming that does not destroy cell identity
Key Differentiators
Broadened senotherapeutics capabilities through acquisition of Dorian Therapeutics
Clinical Focus
Aging; Cellular Therapy; Regenerative Medicine
Company Info
- Business Model
- Service
- Founded
- 2022
- Total Funding
- 3,000,000,000
- Website
- www.altoslabs.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Preclinical: Demonstrated lifespan and healthspan extension in mouse models. Clinical: Early human safety testing initiated August 2025. FDA status: No IND approval or clinical trials launched yet. Acquired Dorian programs showing promise in lung fibrosis and osteoarthritis models. CMO appointment (Dr. Joan Mannick) signals clinical advancement ahead.
MedStartr Index Score
?What do you think of Altos Labs?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.